Skip main navigation
International Stroke Conference 2023 Poster Abstracts
Session Title: Translational Basic Science Posters I

Abstract WP247: Amylin, A Diabetes-associated Amyloid-forming Peptide, Accumulates In Thrombi And On Red Blood Cells - A New Biomarker For Stroke?

Originally published 2023;54:AWP247

    Emergent large vessel occlusions result in severe ischemic stroke without appropriate treatment with thrombolysis and/or mechanical thrombectomy. Type-2 diabetes mellitus (T2DM) is a major risk factor in stroke, with 25% of ischemic attacks occurring in individuals with T2DM. T2DM diagnosis is also associated with poorer functional outcomes, prolonged hospitalizations, and increased risk of recurrent stroke. Amylin, a peptide co-secreted with insulin in pancreatic β-cells, is hypersecreted in T2DM and readily forms neurotoxic oligomers which deposit in brain parenchyma. Due to amylin’s role in T2DM and T2DM’s relationship to stroke, we anticipated an increased level of amylin would be deposited on red blood cells (RBCs) of stroke patients when compared to non-stroke patients. Additionally, we anticipated an increased level of amylin immunoreactivity (AIR) in clot lysates when compared to RBC lysates and plasma. Blood samples and thrombi (n=47) were collected from patients undergoing mechanical thrombectomies for stroke while blood samples (n=21) were collected from patients with non-stroke neurological conditions. Samples were lysed and assayed for total protein concentration and intensity of AIR. Amylin uptake coefficients (AUCs) demonstrating the proportionality of amylin deposited on RBCs compared to total circulating amylin were calculated. After normalizing to total protein concentration, analysis revealed a significantly increased level of AIR in stroke clots when compared to stroke and non-stroke plasma and RBC lysates (p<0.001 for each). Additionally, a significant increase (p<0.0073) in AUC was found in stroke versus non-stroke. In summary, amylin accumulates in thrombi and deposits on RBCs of stroke patients. Further research into amylin’s potential role in thrombus formation is justified. Future studies are also needed to determine if stroke severity is associated with amylin level in thrombi and if T2DM exacerbates amylin-stroke pathology.


    Author Disclosures: For author disclosure information, please visit the ASA’s International Stroke Conference 2023 Online Program Planner and search for the abstract title.


    eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

    Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.